Anuh Pharma Limited · NSE:ANUHPHR
Anuh Pharma — 9M FY2024 Earnings Presentation
34 slides from Anuh Pharma's earnings presentation, Feb 19, 2024
Slide 1: Cover letter to BSE for Investor Presentation Q3 FY2024
Date: 19th February, 2024 To, The Manager (Listing) BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai - 400 001 Ref: Scrip Code No. 506260 Sub: Investor Presentation – Q3 FY2024 Dear Sir/Madam, We are enclosing herewith our Company’s Investor Presentation for the Q3 2024. Kindly take
Slide 2: Anuh Pharma Ltd. Investor Presentation 9M FY2024
ANUH PHARMA LTD. Investor Presentation 9M FY2024 (Feb‐24) BSE Scrip Code: 506260 Bloomberg Code: ANUH IN Reuters Code: ANUH.BO www.anuhpharma.com 1
Slide 3: Safe Harbor Statement
Safe Harbor Statement This presentation may include certain “forward looking statements”, based on current expectations, within the meaning of applicable laws and regulations. Actual results may differ and the Company does not guarantee realization of these statements. The Company also disclaims any
Slide 4: Table of content
Table of content 01 Q3FY 2024 & FY 2023 HIGHLIGHTS 02 COMPANY OVERVIEW 03 INFRASTRUCTURE 04 FUTURE OUTLOOK 05 CORPORATE SOCIAL RESPONSIBILITY ANUH PHARMA LTD.
Slide 5: 9M FY 2024 & FY 2023 Highlights
01 9M FY 2024 & FY 2023 HIGHLIGHTS
Slide 6: Message from Joint MD
Message from Joint MD Dear Valued Share Holder, We are delighted to present to you the Investor presentation for 3rd quarter leading the way for the Financial Year 2023‐ 24. Revenue: The company has clocked Revenue of Rs 175.75 CR. for the Q3 and 492.38 CR. for 9M, growth rate of 31% YOY. Profit: Co
Slide 7: Message from Joint MD
Message from Joint MD R&D Company has recently launched new product like Vildagliptin, Acebrophylline, Amodiquine, Moxifloxacin and Allopurinol. This products combined is expected to give additional top line of 50 crore in FY25. The R&D department is expected to give 6 new products in next 9 months.
Slide 8: Financial performance highlights (last 5 years)
Financial performance highlights (last 5 years) EBITDA (INR in Cr.) Total Revenue (INR in Cr.) 537 57 492 55 52 443 325 312 34 27 18‐19 19‐20 20‐21 21‐22 22‐23 18‐19 19‐20 20‐21 21‐22 22‐23 PBT (INR in Cr.) PAT (INR in Cr.) 47 39 39 36 32 31 28 23 19 14 7 18‐19 19‐20 20‐21 21‐22 22‐23
Slide 9: Business mix revenue contribution
Business mix revenue contribution Top 5 customers contribution Revenue Split (Rs. In Cr.) 46% 40% 482 35% 31% 33% 33% 370 265 217 212 158 Domestic Export Total 9M FY 24 9M FY 23 9M FY 24 9M FY 23 Export Sales Domestic Sales Total Sales GEOGRAPHICAL EXPORT SALES DURING 9M FY24 GEOGRAPHICAL EXPORT SAL
Slide 10: Product mix revenue contribution
Product mix revenue contribution 142 9M FY 23 9M FY 24 115 80 82 68 63 57 41 30 32 26 25 21 19 17 17 8 9 Erythromycin Higher Chloramhenicol Pyrazinamide Sulphadoxine Cortico Ambroxol HCL Gliclazide Other Items Macrolides Steroids INR in Cr. 9
Slide 11: Track Record
Track Record EBITDA Margin % Net Profit Margin % 12.76 7.29 6.58 6.86 10.67 10.69 10.89 6.28 8.79 4.66 18‐19 19‐20 20‐21 21‐22 22‐23 18‐19 19‐20 20‐21 21‐22 22‐23 ROE (%) ROCE (%) 16 16 21 20 20 14 15 19 9 12 18‐19 19‐20 20‐21 21‐22 22‐23 18‐19 19‐20 20‐21 21‐22 22‐23 10
Slide 12: Track Record
Track Record Outflow of Dividend (INR in Cr.) Current ratio 17 2.03 1.98 1.91 1.70 10 1.37 8 9 8 18‐19 19‐20 20‐21 21‐22 22‐23 18‐19 19‐20 20‐21 21‐22 22‐23 Debt to Equity Net Working Capital (Days) 0.27 57 58 56 47 35 0.07 0.03 0.01 ‐ 18‐19 19‐20 20‐21 21‐22 22‐23 18‐19 19‐20 20‐21 21‐22 22‐23 11
Slide 13: 9M FY 24 and FY 23 Financial Performance
9M FY 24 and FY 23 Financial Performance Rs. In Cr. 3 months 3 months Variance 9 months 9 months Variance Variance Financial FY FY ended ended (%) ended ended (%) (%) Highlights 2023 2022 31/12/2023 30/09/2023 QoQ 31/12/2023 31/12/2022 YoY YoY Operating Revenue 172.10 149.53 15 483.11 370.18 31 527.
Slide 14: FY 23 Financial Performance
FY 23 Financial Performance Operating Revenue (Rs. In Cr.) Operating Profit * (Rs. In Cr.) 527.48 114.75 486.64 98.10 FY23 FY22 FY23 FY22 * (PBT+ Dep +Other Exps.) EBITDA (Rs. In Cr.) PAT (Rs. In Cr.) 57.39 36.18 52.04 30.56 FY23 FY22 FY23 FY22 13
Slide 15: Company Overview
02 COMPANY OVERVIEW
Slide 16: Company Overview
Company Overview The Company derived ~55% of its revenues from exports in FY22‐23. The Company has strong marketing partnerships with 350 customers in over 57 countries including Europe, Mexico and South Africa. The expansion project with state of the art manufacturing facility targeted at regulated
Slide 17: Journey So Far
Journey So Far… Year Achievements 1989 Started manufacturing Erythromycin salts with capacity of 150 MTPA , followed by doubling the capacity to 300 MTPA in 1995. 2002 Received WHO‐GMP for its facilities. 2006 Doubled the capacity by acquiring new plot of 1800 SQMT to expand the output capacity 600
Slide 18: Journey So Far
Journey So Far… Year Achievements Received EU GMP for Erythromycin, Erythromycin ethyl succinate, Pyrazinamide, Pyrimethmine and Sulphadoxine from AEMPS 2019 Spain. 2019 Enhanced the capacity by acquiring new plot of 7800 SQMT to expand the output capacity by 600 MTPA. 2019 USFDA inspection passed s
Slide 19: Competitive Advantage
Competitive Advantage Market leadership: Erythromycin salts Competitive Advantage Pyrazinamide • Regulatory approvals • Environmental health and Safety Compliance (Audited an Sulfadoxine approved by Multinational companies). Ambroxol HCL • Well diversified sourcing with backward integration in key p
Slide 20: Key Management Personnel & Senior Management
Key Management Personnel & Senior Management VC VICE CHAIRMAN MR. BIPIN SHAH JMD JMD JOINT JOINT MANAGING MANAGING DIRECTOR DIRECTOR MR. RITESH SHAH MR. VIVEK SHAH VP CS & VP R&D VP MARKETING CFO COMPLIANCE TECHNICAL HEAD QUALITY OFFICER MR. RAJU MR. DARSHAN Mrs. Jinal Mehtalia DR. RAJIV DR. UDAY MR
Slide 21: Key Management Personnel & Senior Management
Key Management Personnel & Senior Management Name Designation Profile Mr. Jasvantlal G Chairman Graduate in Economics, Law and Post graduate in Business Management, FCS; He has discharged responsibilities in Shah senior positions in two reputed indigenous business groups as well as number of interna
Slide 22: Latest Shareholding Pattern
Latest Shareholding Pattern Public 30.06 % Promoter & Promoter Group, 69.94 % Market capitalization INR 1,035 Cr. (As on 16th February, 2024) Free float market capitalization INR 311 Cr. (As on 16th February, 2024) 21
Slide 23: Infrastructure
03 INFRASTRUCTURE
Slide 24: State of Art manufacturing facility
State of Art manufacturing facility • Anuh Pharma has a EUGMP/ WHO Pre qualified approved manufacturing facility at Tarapur spread across 11,400 sq. meters with 8 API’s blocks and 1 intermediate block with total capacity of 1800 MTPA – this includes new expanded capacity. • With commissioning of Zer
Slide 25: Major Equipment Capabilities
Major Equipment Capabilities SNO. EQUIPMENT MOC CAPACITY QTY NOTES: 1 REACTOR WITH CONDENSER AND RECEIVER SS 316 650 L TO 10 KL 37 • The entire area is supplied with 3 Micron Filtered Forced Draft Ventilation. 2 REACTOR WITH CONDENSER AND RECEIVER GLR 500 L TO 10 KL 8 • The utilities are connected s
Slide 26: Major Equipment- Utility Capabilities
Major Equipment- Utility Capabilities SNO. EQUIPMENT QTY CAPACITY USE 1 BOILER 2 2000 KG/HR WITH PRESSURE OF 10 GENERATION OF STEAM KG/CM² 2 COMPRESSOR 4 700 CFM FOR AIR JET MILLING 3 WATER SYSTEM 2 3000 LITRES/HR FOR SUPPLY OF PURIFIED WATER 4 CHILLING PLANT 5 90TR, 95 TR & 270TR,220&297 TR FOR CHI
Slide 27: Other Facilitates
Other Facilitates The entire facility is equipped with latest Fire Fighting and Safety Measures. Zero Liquid Discharge Effluent Control system for treating 100% of Generated Pollution. 100% Power Backup via dedicated power line from Power Distributor to our premises. Adjoining office and a Training
Slide 28: Dedicated Research & Development Facility
Dedicated Research & Development Facility FACILITATE ACTIVITIES LAB SCALE REACTION THAT LEAD TO DEVELOP PROCESSES AND BATCHES TO VALIDATE CHARACTERIZATION AND PRODUCTS. RESEARCH PROFILING OF PRODUCTS. ANALYTICAL DEV CHEMICAL SYNTHESIS PILOT PLANT IN HOUSE R&D LAB APL NEW PRODUCTS & PROCESSES A dedic
Slide 29: Future Outlook
04 FUTURE OUTLOOK
Slide 30: Future Outlook – Growth Strategy
Future Outlook – Growth Strategy Marketing: • Increase Contribution from new Geographies especially in Japan, Vietnam and South Korea. • Continued focus on increasing market share in Corticosteroids, for which manufacturing capacity at L&L site is enhanced to 12 MTPA. • To tap opportunities with CEP
Slide 31: Future Outlook – Product under development
Future Outlook – Product under development Sr. No Product Name Therapeutic application 1) Sulfadimethoxine Anti Protozoal 2) Citicoline sodium Neuroprotective 3) Ticagrelor Anti Platelet 4) Dapagliflozin Anti Diabetic 5) Empagliflozin Anti Diabetic 6) Canagliflozin Anti Diabetic 30
Slide 32: Corporate Social Responsibility
05 CORPORATE SOCIAL RESPONSIBILITY
Slide 33: CSR: Servicing Society for better tomorrow
CSR …. Servicing Society for better tomorrow • APL takes corporate sustainability and social responsibility as a voluntary commitment rather than an obligation. We engage in social activities encompassing education, healthcare, sanitation, vocational skill building, rural development & natural conse
Slide 34: Thank You
Thank You For specific queries please feel free to contact; Mr. Darshan Rampariya (CFO) darshan.r@anuhpharma.com